Ligand validation:6I2A

RIP: beta-D-ribopyranose

RIP is a Ligand Of Interest in 6I2A designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6I2A_RIP_D_101	97%	68%	0.053	0.968	0.23	1	-	-	0	0	100%	0.9
5OUC_RIP_E_101	16%	52%	0.191	0.817	0.79	1.06	-	1	0	0	70%	0.7
5OUA_RIP_B_101	7%	51%	0.228	0.736	0.88	1	1	1	0	0	70%	0.7
6EMA_RIP_C_101	6%	69%	0.19	0.629	0.21	0.96	-	1	1	0	100%	1
6EM7_RIP_D_101	4%	60%	0.305	0.705	0.88	0.67	1	-	0	0	80%	0.8
5OT3_RIP_D_101	3%	72%	0.242	0.643	0.54	0.53	-	-	0	0	60%	0.6
2IOY_RIP_B_402	96%	57%	0.068	0.979	0.69	0.96	-	-	0	0	100%	1
4RY0_RIP_A_401	95%	37%	0.089	0.992	1.13	1.32	2	1	0	0	100%	1
3P13_RIP_B_201	75%	50%	0.126	0.959	0.64	1.27	-	2	0	0	100%	1
6I2H_RIP_D_101	73%	70%	0.086	0.912	0.34	0.82	-	-	0	0	100%	0.9
6X8Y_RIP_A_201	73%	62%	0.132	0.958	0.67	0.77	-	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.